Skip to content

Cost benefit evaluation of routine influenza immunisation in subjects 65-74 years of age

Cost benefit evaluation of routine influenza immunisation in subjects 65-74 years of age

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN27879030
Enrollment
Unknown
Registered
2003-04-25
Start date
1999-09-01
Completion date
Unknown
Last updated
2019-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection and infestations: Influenza Infections and Infestations Influenza

Interventions

Please note that, as of 14 January 2008, the anticipated end date of this trail has been updated from 31 August 2001 to 31 August 2002. Interventions: 1. Pneumococcal

Sponsors

Department of Health (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 65-74 year olds

Exclusion criteria

Exclusion criteria: Aged over 75 years

Design outcomes

Primary

MeasureTime frame
1.1 Hospital admission with or without respiratory illness 1.2 GP consultation for respiratory and non-respiratory disease 1.3 Self- reported patient illness and over the counter medication 1.4 Quality of Life measures at 3, 6, 9 and 12 months post vaccination. 2. To determine the cost effectiveness of the vaccination. 3. To determine whether factors such as age, sex, co-morbidity and social class affects, 3.1 entry into the trial, 3.2 the receipt or otherwise of the influenza vaccination outside the clinical trial, 3.3 cost effectiveness.

Secondary

MeasureTime frame
Not provided at time of registration.

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026